Icosavax is developing vaccines to protect older adults against multiple respiratory viruses. Icosavax’s approach centers around their virus-like particles (VLPs) - these VLPs are designed to mimic the structure of viruses and therefore the body sees the VLPs as a virus, as opposed to soluble antigens that are being used by mRNA-derived vaccines. Therefore, Icosavax hopes the VLPs will empower a better immune response that is stronger and more durable. Currently, Icosavax is progressing multiple assets including a Phase 2 clinical trials in progress for the prevention of RSV and hMPV.

Icosavax

Founded: 2018
Location: Seattle, WA
Employee range: 11 - 50
Clinical stage: Clin2
Therapy area: RSV
Drug types: VAC, INF
Lead product: IVX-A12
Funding: $67.8M stock May 2023; $209M IPO Jul 2021; $100M B Apr 2021; $51M A Oct 2019

Drug notes:

About:

Jobs: